Poster 130 Sustained Efficacy of IncobotulinumtoxinA (XEOMIN; botulinum neurotoxin type A, free from accessory proteins) in Cervical Dystonia Demonstrated by Investigator‐ and Patient‐rated Outcomes
Bibliographic record
Abstract
D. Dressler, Allergan, consulting fees or other remuneration; Eisai, consulting fees or other remuneration; Ipsen, consulting fees or other remuneration; Merz, consulting fees or other remuneration. To assess the long-term efficacy and tolerability of incobotulinumtoxinA in cervical dystonia (CD) in a setting similar to clinical practice. Prospective, multicenter, open-label, single-arm phase IV study (≤121 weeks duration). 17 centers across Germany. Patients with CD. Patients received up to 5 injection series (IS) of incobotulinumtoxinA. The interval between each injection session was 10-24 weeks, depending on the clinical need. Investigators were free to choose the pattern of muscles injected, the number of injection sites, and the total dose injected (maximum, 300 U). Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), Dystonia Discomfort Scale (DDS) (a newly developed patient diary), Global Assessment of Efficacy (as rated by the investigator), Patient Evaluation of Global Response, Investigator Global Assessment of Tolerability. Seventy-six patients were enrolled. Nineteen patients were treatment naïve to botulinum toxin, and 57 had received previous injections of botulinum neurotoxin type A. Mean change in TWSTRS-Total score from study baseline to 4 weeks after each IS was –11.7 (IS 1), –13.6 (IS 2), –13.4 (IS 3), –13.9 (IS 4), and –14.3 (IS 5) (data of Full Analysis Set; missing values imputed with LOCF). Similar improvements in DDS score were observed. The absolute change in DDS score was stable across all IS. After each IS, up to 81% of investigators rated efficacy as “good” or “very good.” The proportion of patients rating global response as +2 (moderate improvement) or greater was 77.6% (IS 1), 67.1% (IS 2), 72.4% (IS 3), 64.5% (IS 4), and 78.9% (IS 5). The Investigator Global Assessment of Tolerability was reported as “good” or “very good” for most patients. IncobotulinumtoxinA showed sustained efficacy and was well tolerated for the treatment of CD in a study with a duration up to 121 weeks. Clinical measures of efficacy were supported by investigator- and patient-rated outcomes.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".